Kimberly-Clark Health Care announces that it will increase the price of certain products within its portfolio most impacted by rapidly escalating costs of raw materials derived from oil.
In 24 months, market costs have almost tripled for high grade polypropylene polymer, which comprises the nonwoven materials used in many of Kimberly-Clark Health Cares single-use products. The cost of butadiene and acrylonitrile, the main raw materials used to produce nitrile synthetic gloves, have experienced similar cost increases during the same timeframe.
Although Kimberly-Clark Health Care planned for rising costs of raw materials, inflationary pressures have been beyond expectations and have outweighed a series of aggressive and sustained cost reduction measures implemented across the business. All areas of the business have been examined thoroughly, including a reduction in energy and resource use, a part of the company's ongoing sustainability program.
"By no means are we done looking at further offsets to reduce the price pressure for our customers and well continue to do so," says John Amat, vice president of global sales and marketing. "In the meantime, however, its important that we continue to deliver the same high quality products that our customers expect, and this means maintaining top quality raw materials."
The price increases will affect Kimberly-Clarks single-use medical products and are effective subject to notification periods.
Unraveling a Candida auris Outbreak: Infection Control Challenges in a Burn ICU
March 19th 2025A Candida auris outbreak in a burn intensive care unit (BICU) in Illinois has highlighted the persistent challenges of infection control in high-risk health care settings. Despite rigorous containment efforts, this multidrug-resistant fungal pathogen continued to spread, underscoring the need for enhanced prevention strategies, environmental monitoring, and genomic surveillance.
Unmasking Long COVID: Dr Noah Greenspan on Recovery, Research Gaps, and the Future of Treatment
March 18th 2025Dr Noah Greenspan discusses the evolving understanding of long COVID, current treatment strategies, diagnostic challenges, and the critical need for research and awareness in post-viral syndromes.